Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease (ELITE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03208465|
Recruitment Status : Recruiting
First Posted : July 5, 2017
Last Update Posted : June 25, 2018
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus Coronary Disease||Drug: Empagliflozin Drug: Sitagliptin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial|
|Actual Study Start Date :||August 7, 2017|
|Estimated Primary Completion Date :||September 30, 2020|
|Estimated Study Completion Date :||April 30, 2021|
|Experimental: Patients with Empagliflozin||
In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
|Active Comparator: Patients with Sitagliptin||
In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
- Percent change in global myocardial perfusion reserve (MPR) index [ Time Frame: 6 months ]
Percent change in global myocardial perfusion reserve (MPR) index defined as (global MPR index at 6 months - global MPR index at baseline)/(global MPR index at baseline)x100.
MPR index=stress myocardial flow/rest myocardial flow
- Percent change in regional MPR index [ Time Frame: 6 months ]Percent change in regional MPR index defined as (regional MPR index at 6 months - regional MPR index at baseline)/(regional MPR index at baseline)x100.
- Absolute change in regional MPR index [ Time Frame: 6 months ]
- Absolute change in global MPR index [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03208465
|Contact: Cheol-whan Lee, MDemail@example.com|
|Korea, Republic of|
|Asan Medical Center||Recruiting|
|Seoul, Korea, Republic of|
|Contact: Cheol-whan Lee, MD +82230103150 firstname.lastname@example.org|
|Principal Investigator: Cheol-Whan Lee, MD|